deepc Partners with Intrasense to Accelerate Oncology Pathways in Routine CT

Munich, Germany & Montpellier, France, January 28, 2026 — Abdominal CT is one of the biggest pressure points in radiology. High volumes, long reading lists, and complex oncology follow-up cases make it challenging to ensure both accurate and timely reporting. When subtle liver, bone, or pancreatic findings remain buried in thousands of slices, small oversights can slow entire pathways. Intrasense is addressing this operational reality with DUOnco™, a suite of three standalone AI solutions co-developed with Guerbet that support earlier lesion visibility inside everyday workflows. Intrasense and deepc are partnering to make these solutions available through deepcOS®.

Supporting radiologists with a safety net in oncology imaging

Despite technological advances in medical imaging, detecting subtle liver, bone, and pancreatic lesions remains a challenge, particularly when analyzing routine CT scans. Intrasense’s DUOnco™ Liver, DUOnco™ Bone, and DUOnco™ Pancreas are designed to act as a safety net by surfacing subtle findings that may otherwise go unnoticed, helping radiologists maintain pace without compromising focus.

DUOnco™ Liver is a solution for automatic detection of focal liver lesions, assisting radiologists in evaluating the liver, a primary site of metastasis¹. It provides automatic detection, segmentation and quantification of suspicious lesions. According to an internal study, DUOnco™ Liver achieves 94% sensitivity², providing a safety net that supports the detection of small lesions often overlooked. In a retrospective study, it detected over half of liver metastases initially missed by radiologists³, supporting more consistent and reliable lesion visibility.

DUOnco™ Bone identifies focal bone lesions, including primary tumors and metastatic involvement, enhancing reliable detection even in high-volume exams. In routine clinical practice, up to 30% of bone lesions may go undetected on CT scans⁴, highlighting the need for additional decision-support tools. An internal study reports a sensitivity of up to 90% for detecting metastases identified by two annotators, demonstrating the tool’s effectiveness. DUOnco™ Bone is intended to streamline the review of bone findings and support consistent interpretation within oncology workflows.

DUOnco™ Pancreas identifies subtle pancreatic lesions and automatically detects and measures the main pancreatic duct. Because the pancreas is often not carefully examined in asymptomatic patients, small lesions can easily be missed. By highlighting these findings, DUOnco™ Pancreas aims to enable radiologists to detect lesions at an early stage, when they are still small enough to be surgically treated. Its accuracy in detecting lesions has been demonstrated in an internal study, which reports 95% sensitivity and 90% specificity. Furthermore, the software was able to detect in about half of patients before diagnosis⁶, highlighting its potential to support earlier detection and improved clinical outcomes.

These AI tools are designed to support abdominal CT scan analysis by automatically detecting suspicious lesions and integrating results seamlessly into healthcare systems, simplifying radiologists’ workflow. This helps optimise overall care pathways.

Making oncology support accessible through deepcOS®

Integrating DUOnco™ modules on deepcOS® places these capabilities directly inside PACS and reporting systems. Radiologists receive support without changing tools, which keeps the reporting flow uninterrupted. For IT teams, deepcOS® offers secure, centralised deployment that simplifies maintenance and preserves control of data flows. For hospital leaders, it provides a scalable way to introduce validated oncology tools without adding friction to clinical operations.

This partnership confirms Intrasense's ability to transform identified clinical needs into concrete, functional solutions that are valued by radiologists and industry professionals.

Advancing meaningful use of AI to protect departmental flow

Radiology teams need AI that reduces slowdowns, ensures consistent reporting, and supports timely escalation to oncology when it matters. This partnership brings together focused oncology algorithms and an integration framework built for everyday clinical use. AI, which functions as a 'second pair of eyes' to enhance diagnostic confidence, acts as an excellent oncology safety net, providing essential information for faster and more accurate clinical decision-making. By making key lesion cues visible earlier in the reading process, clinicians can manage caseloads more efficiently and support oncology pathways with greater consistency and confidence.